WO2022157747 - PHARMACEUTICAL GLP PEPTIDE COMPOSITIONS AND METHODS OF PREPARATION THEREOF
National phase entry:
Publication Number
WO/2022/157747
Publication Date
28.07.2022
International Application No.
PCT/IB2022/050644
International Filing Date
25.01.2022
Title **
[English]
PHARMACEUTICAL GLP PEPTIDE COMPOSITIONS AND METHODS OF PREPARATION THEREOF
[French]
COMPOSITIONS PEPTIDIQUES PHARMACEUTIQUES ET LEURS PROCÉDÉS DE PRÉPARATION
Applicants **
MYLAN IRELAND LIMITED
Inventors
BANASIAK, Katarzyna
SIVADAS, Neeraj
FITZGERALD, Michael, Paul
DOWNES, Claire
CARR, Paul
Priority Data
63/141,230
25.01.2021
US
63/189,863
18.05.2021
US
63/226,020
27.07.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2569 | |
| EPO | Filing, Examination, Granting | 13339 | |
| Japan | Filing, Examination, Granting | 2452 | |
| South Korea | Filing, Examination, Granting | 2652 | |
| USA | Filing, Examination, Granting | 8540 |
Total:
29,552
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Disclosed herein is a stabilized peptide composition that includes a glucagon-like peptide and a stabilizer. The stabilizer may be a stabilizing peptide having the same amino acid sequence as the glucagon-like peptide except the stabilizing peptide has at least one sequence alteration that may be a truncation, a deletion, a substitution and/or an insertion. Also disclosed are methods for making the stabilized peptide composition and its use for treating patients in need thereof.[French]
L'invention concerne une composition peptidique stabilisée qui comprend un peptide de type glucagon et un stabilisant. Le stabilisant peut être un peptide de stabilisation présentant la même séquence d'acides aminés que le peptide de type glucagon, à l'exception du peptide de stabilisation, et présente au moins une altération de séquence qui peut être une troncature, une délétion, une substitution et/ou une insertion. L'invention concerne également des procédés de fabrication de la composition peptidique stabilisée et son utilisation pour traiter des patients en ayant besoin.